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Abstract
Colorectal cancer (CRC) remains one of the major pub-
lic health problems throughout the world. Originally 
depicted as a multi-step dynamical disease, CRC devel-
ops slowly over several years and progresses through 
cytologically distinct benign and malignant states, from 
single crypt lesions through adenoma, to malignant 
carcinoma with the potential for invasion and metasta-
sis. Moving from histological observations since a long 
time, it has been recognized that inflammation and 
immunity actively participate in the pathogenesis, sur-
veillance and progression of CRC. The advent of immu-
nohistochemical techniques and of animal models has 
improved our understanding of the immune dynamical 
system in CRC. It is well known that immune cells have 
variable behavior controlled by complex interactions in 
the tumor microenvironment. Advances in immunology 
and molecular biology have shown that CRC is immu-
nogenic and that host immune responses influence sur-
vival. Several lines of evidence support the concept that 
tumor stromal cells, are not merely a scaffold, but rath-
er they influence growth, survival, and invasiveness of 
cancer cells, dynamically contributing to the tumor mi-
croenvironment, together with immune cells. Different 
types of immune cells infiltrate CRC, comprising cells 
of both the innate and adaptive immune system. A rel-
evant issue is to unravel the discrepancy between the 
inhibitory effects on cancer growth exerted by the local 
immune response and the promoting effects on cancer 
proliferation, invasion, and dissemination induced by 
some types of inflammatory cells. Here, we sought to 
discuss the role played by innate and adaptive immune 
system in the local progression and metastasis of CRC, 
and the prognostic information that we can currently 
understand and exploit.
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INTRODUCTION
Despite progresses in our biological and clinical knowl-
edge, colorectal cancer (CRC) remains one of  the major 
public health problems throughout the world[1]. By its fre-
quency, CRC ranks third in men and women worldwide[1]. 
In addition, CRC continues to be one of  the most com-
mon fatal types of  cancer. Originally depicted as a multi-
step dynamical disease, CRC develops slowly over several 
years and progresses through cytologically distinct benign 
and malignant states, from single crypt lesions through 
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adenoma, to malignant carcinoma with the potential for 
invasion and metastasis[2,3]. According to the theory of  
multi-step carcinogenesis, colorectal epithelial cells ac-
cumulate a number of  molecular changes to eventually 
become fully malignant[4,5]. In spite of  unifying theories, 
genetic and epigenetic events during the carcinogenesis 
process differ considerably from tumor to tumor. Thus, 
CRC is not a single disease; rather it encompasses differ-
ent molecular and pathological entities with a wide range 
of  clinical behaviors[6]. At the molecular level, CRC is the 
tip of  an iceberg the basis of  which encloses a complex 
array of  gene alterations, affecting supra-molecular pro-
cesses. Essentially, like individual fingerprints, each tumor 
arises and behaves in a unique fashion that is unlikely to 
be exactly recapitulated by any other tumor. Neverthe-
less, molecular changes allows for a categorization of  
CRC, which is largely accepted, although likely to over-
simplistic. It has been demonstrated that main genetic 
and epigenetic features, such as microsatellite instability 
(MSI), chromosomal instability, CpG island methylator 
phenotype (CIMP) or global DNA hypomethylation, 
lead to alterations of  gene function on a genome-wide 
scale. It is known that activation of  oncogenes, including 
KRAS, BRAF, PIK3CA and TP53, affects intracellular 
signaling pathways[6,7]. The suppressor pathway is dis-
rupted in CRC with chromosomal instability occurring in 
the majority of  CRCs (approximately 85%), which have a 
molecular profile characterized by specific chromosomal 
amplifications and transformations, aneuploidy, and loss 
of  heterozygosity[6-8]. Differently, CRCs of  the mutator 
pathway (approximately 15%) have a defective DNA 
mismatch repair system, which leads to accumulation of  
thousands of  unrepaired mutations[8]. This inability to 
repair DNA slippage errors and mismatches can easily be 
demonstrated because it results in variability in the length 
of  DNA microsatellites, formed by repetitive sequences, 
that is MSI. It is accepted that MSI CRCs have a hetero-
geneous histological appearance, better prognosis due to 
a reduced metastatic potential, and a different response 
to chemotherapy[9-14].
Histopathological examination reveals that likely other 
solid tumors, CRC are associated with diverse immune 
cell infiltrates[15-20], and that in the cancer context, epi-
thelial cells coexist with extracellular matrix components 
and non-neoplastic cell types, including fibroblasts, myo-
fibroblasts, adipocytes, endothelial cells, pericytes, which 
collectively form the tumor stroma. Several lines of  evi-
dence support the concept that tumor stromal cells, are 
not merely a scaffold, but rather they influence growth, 
survival, and invasiveness of  cancer cells, dynamically 
contributing to the tumor microenvironment, together 
with immune cells[20-25]. The types of  immune system cells 
that are found infiltrating CRC consist of  cells of  the in-
nate immune system i.e., macrophages, neutrophils, mast 
cells and natural killer cells, as well as cells associated with 
an adaptive immune response i.e., T and B lymphocytes. 
Although it is commonly thought that an immune re-
sponse localized to the tumor inhibit cancer growth, it is 
clear that some types of  tumor-associated inflammation 
may also exert an opposite action, at least at some point 
of  CRC natural history[26] (Figure 1). Here we sought to 
briefly review these two contradictory aspects of  the im-
mune response to CRC. 
INNATE IMMUNITY AND COLORECTAL 
CANCER 
It is well known that innate immunity represents the 
body’s first defense or “gut reaction” to an abnormal sit-
uation, such as cancer, and does not involve specific rec-
ognition of  immunogenic peptides, or antigens[20]. Aside 
T and B lymphocytes , innate immune cells orchestrate 
an inflammatory environment that may function to ei-
ther stimulate or inhibit cancer growth[20]. Various innate 
immune cells have been implicated in CRC development 
and progression[15,27,28]. Among these, macrophages, are 
a primary source of  secreted pro-inflammatory cyto-
kines, and are generally distinguished as type 1 (M1) or 
type 2 (M2)[29-31]. M1s generally have an interleukin (IL) 
12lowIL-10high phenotype, show impaired expression of  
reactive nitrogen intermediates, poor antigen presenta-
tion and have tumoricidal capacity, while show high 
expression of  angiogenic factors [including Vascular-
endothelial growth factor (VEGF) epidermal-growth 
factor (EGF) and semaphorin 4D], metalloproteases 
(MMPs) and cathepsins as well as of  the growth arrest-
specific protein 6 (GAS6)[29-32]. Additionally, M1s can sup-
port T-helper 1 (Th1) adaptive immunity[33]. Conversely, 
M2s secrete immunosuppressive cytokines and promote 
tumor growth[22,34]. It has been shown that cancer cells 
shape their interaction with macrophages by escaping 
phagocytosis and by promoting a M2-like polarization 
throughout chemokines and polarizing cytokines includ-
ing chemokine (C-C motif) ligand 2 (CCL2), colony 
stimulating factor 1 (CSF1), macrophage slowing factor 
(MSF), tumor necrosis factor-alpha (TNF-α, IL-10 and 
transforming growth factor-β (TGF-β).
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Figure 1  Immune cells have variable behavior controlled by complex in-
teractions in the tumor microenvironment. Although it is commonly thought 
that an immune response localized to the tumor inhibit cancer growth, it is now 
clear that some types of tumor-associated inflammation can exert an opposite 
action.
Among the cells with M2 phenotype, the tumor-as-
sociated macrophages (TAM) have been shown as ca-
pable of  secreting proteases that enhance invasion and 
metastases, together with a range of  cytokines inhibit-
ing an adaptive tumor-specific immune response, and 
angiogenic factors that increase neovascularity. In pa-
tients with CRC, macrophages are usually found located 
around necrotic areas of  tumor and the advancing tumor 
margin[28]. Their role in CRC still remains controversial. 
While, it was originally thought that the main function 
of  TAMs was a direct cytotoxic effects on tumor cells, 
phagocytosis apoptotic/necrotic cell debris, and pres-
ent tumor-associated antigens to T lymphocytes, current 
evidences suggest that inflammation and TAMs can also 
promote tumor growth and metastasis. Kang et al[35] have 
recently highlighted an association between intra-tumoral 
TAM densities with CRC malignant aggressiveness. Ad-
ditionally, increased frequencies of  intra-tumoral TAM 
have been associated with high levels of  MMP type 2 
and 9 expression in CRC cells[36,37]. These findings are in 
accord with a previous cell-line study showing that co-
culturing of  tumor cells with macrophages enhances can-
cer cell migration, invasiveness, and MMP-2 and MMP-9 
secretion[35]. 
Kaler et al[38] have recently established that macro-
phages promote Wnt signaling pathway in CRC cells and 
thus enhance their proliferation, and demonstrated that 
macrophages exert their pro-tumorigenic activity mainly 
through the release of  IL-1β. The same authors demon-
strated that tumor necrosis factor related apoptosis in-
ducing ligand (TRAIL) induced apoptosis of  CRC cells is 
inhibited by macrophage derived IL-1β, and showed that 
macrophages and recombinant IL-1β counteract TRAIL-
induced apoptosis through activation of  Wnt signaling 
and stabilization of  the nuclear transcription factor Snail 
in tumor cells.
A number of  studies have also shown that macro-
phages can release a vast diversity of  cytokines, proteolyt-
ic enzymes, growth factors, and inflammatory mediators 
that may directly influence and stimulate the growth and 
migration of  tumor cells[29-33]. Li et al[39] first reported that 
IL-6 released by macrophage directly promotes CRC cell 
progression. They showed that monocyte/macrophage-
derived IL-6 enhances migration of  HT-29 CRC cells in 
vitro[39]. Although, how IL-6 enhances HT-29 cell migra-
tion still remains unknown, it has been suggested that 
TGF-β may be involved in this process. Using mono-
clonal antibodies to neutralize IL-10 in macrophage su-
pernatant, Li et al[39] found that the IL-6-mediated effects 
on HT-29 CRC cells were all enhanced. Therefore, the 
interaction between IL-6 and IL-10 released from macro-
phage is indeed involved in CRC progression and prog-
nosis. The above findings support the fact that TAMs 
play a regulatory role in the tumor microenvironment 
by modulating secretion of  cytokines such as IL-6 and 
IL-10, thereby causing cancer cells to manipulate their 
microenvironment to facilitate cancer growth[40,41].
TAM activation and maturation is under the influence 
of  the tumor microenvironment. TAMs retain a relatively 
immature phenotype, characterized by a low expression 
of  differentiation-associated antigens in hypoxic micro-
environments[35,42,43]. Conversely to an M2 phenotype 
with pro-tumoral functions in CRC[35], it has been shown 
that the macrophages, especially those secreting IL-12 
and IL-23, infiltrating the tumor front are positively 
correlated with a favorable outcome, which implicates 
TAMs as possessing anti-tumor functions. Forssell et 
al[44] stained with the pan-monocyte/macrophage marker 
CD68 a series of  CRC specimens and showed that the 
higher macrophage infiltration along the tumor invasive 
front correlated with improved survival in colon cancer 
compared to rectal cancer. They concluded that a dense 
macrophage infiltration at the tumor front positively in-
fluences prognosis in colon cancer and that the degree 
of  cell-to-cell contact may influence the balance between 
pro-tumorigenic and anti-tumorigenic properties of  mac-
rophages. High levels of  tissue macrophages have been 
also associated with earlier disease stage, absence of  nod-
al and lymphovascular metastases and an overall better 
prognosis. Zhou et al[45] by analyzing the relationship be-
tween the density of  TAMs and the potential of  hepatic 
metastasis and survival have shown that a higher density 
of  macrophages along the invasive front of  CRC was 
associated with a higher 5-year survival rate. In addition, 
according to Forssell’s scoring system that defines CD68 
hot-spots as small areas among which the infiltration of  
macrophages was considerably above the average level of  
CD68-positive cells, the highest CD68 hot-spot was asso-
ciated with both the incidence of  hepatic metastasis and 
the interval between colon resection and the occurrence 
of  hepatic metastasis[45]. 
The mechanisms behind the anti-tumor effects of  
TAMs have still not been fully elucidated, and seem po-
tentially be ascribed to the M1 phenotype, which is in 
part controlled by the CD4+T lymphocytes and the death 
of  cancer cells[45-47]. It has been ascertained that recruit-
ment of  TAMs contributes to the development of  an 
adaptive immune response against cancer, and the bal-
ance between antigen availability and clearance through 
phagocytosis and subsequent degradation of  senescent 
or apoptotic cells.
It is undeniable that the discrepancies in results be-
tween different studies may be due to a number of  fac-
tors related to the location of  the TAMs and the assess-
ment methods employed. Recent studies have reported 
that different macrophage phenotypes localized to dif-
ferent regions of  the carcinoma have variable effects on 
tumor cells[18,19]. Furthermore, evidences have shown that 
the relationship between TAMs and tumor progression is 
tumor type-dependent.
Other innate immune system cells can be detected in 
CRC microenvironment, including mast cells (MCs), neu-
trophils, natural killer (NK) cells, and eosinophils. 
Nagtegaal et al[48] have shown that peritumoral MCs 
prevent local and distant recurrence, with improved sur-
vival as a consequence. The significant benefit of  MCs on 
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uracil-based chemotherapy increases the number of  NK 
cells[54,55].
Aside the above innate immune cell types, dendritic 
cells (DCs), antigen-presenting cells that are critical to 
the stimulation of  effective anti-tumor adaptive immune 
responses, can become defective in the tumor microen-
vironment and aid in tumor immune evasion by failing 
to stimulate T lymphocytes. It has been suggested that 
the presence of  DCs may be of  significant benefit in 
patients with CRC. Xie et al[56] also demonstrated that the 
presence of  DCs was found predominantly in early com-
pared to later disease stages and mostly located in tumor 
surrounding tissue. Suzuki et al[57] showed the presence 
of  mature CD83+ DCs at the cancer invasive front and 
by light and electron microscopy demonstrated their ag-
gregation into clusters with lymphocytes, the majority of  
which were CD45RO+ T lymphocytes. They concluded 
that mature CD83+ DCs at the invasive margin promote 
T-cell activation for the generation of  tumor specific im-
munity. 
Although, there is growing evidence that the host 
innate immune system has a critical role in regulating 
carcinogenesis, the specific receptors involved and the 
importance of  their interaction with commensal bacte-
ria remain to be elucidated. Two major classes of  innate 
immune receptors, the Toll-like receptors and Nod-like 
receptors, many of  which are upstream of  nuclear factor 
kappa-light-chain-enhancer of  activated B cells (NF-κB), 
have been investigated[58,59]. Particularly, the toll-like re-
ceptors have been implicated in promoting colon tumori-
genesis. Fukata et al[60] have shown that toll-like receptor-4 
(TLR4) is over-expressed in human colitis-associated can-
cer and, that mice deficient in TLR4 are markedly pro-
tected against colitis-associated neoplasia. A high TLR4 
expression in the tumor microenvironment has recently 
been reported as a possible marker of  disease progres-
sion in CRC[60]. Conversely, the role of  nod-like receptors 
in regulating colorectal tumorigenesis remains unclear. 
Chen et al[61] reported an increased intestinal permeability 
associated with enhanced inflammatory cytokine produc-
tion and epithelial cell proliferation in Nod1-deficient 
mice. As the depletion of  the gut microbiota suppressed 
tumor development in Nod1-deficient mice, a link should 
exist between commensal bacteria and host innate Nod1 
signaling pathway involved in the development of  inflam-
mation-mediated CRC.
ADAPTIVE IMMUNITY AND COLORECTAL 
CANCER 
It is today well recognized that cells of  the adaptive im-
mune system are recruited in CRC and colitis-associated 
tumours (CAC), where they have either pro- and anti-
tumorigenic roles. T lymphocytes participate in inflam-
mation, cancer development and progression, as well as 
in anticancer immunity[20-22]. In CAC the adaptive immune 
system seems to have mainly a pro-tumorigenic role, 
while in CRC it may play a double-faced role, being the 
tumor progression in CRC was also highlighted by Gou-
naris et al[49] who reported that depletion of  MCs, either 
by drugs either in MC-deficient mice, led to remission of  
existing polyps. Similar to other immune cell types, high 
numbers of  MCs are associated with earlier CRC disease 
stage and have been proposed as an independent prog-
nostic marker for improved survival[50]. It has also been 
reported that the number of  MCs progressively decreases 
from normal mucosa through premalignant conditions 
and the lowest numbers are seen in cancers. Because 
of  their location, MCs may prevent the metastasis of  
carcinomas that are restricted to the sub-mucosa. In vivo 
studies have observed that destruction of  lymphatic ves-
sels in the peritumoral infiltrate is always accompanied 
by MCs. This led to the hypothesis that MCs degranulate 
in the sub-mucosa when they come into contact with the 
inflammatory infiltrate or CRC cells, thus leading to the 
destruction of  lymphatic vessels and thereby preventing 
further metastasis. Gulubova and Vlaykova[51] proposed 
the MCs density along the invasive front of  the primary 
CRC as a helpful tool for prognosis of  patients after 
surgical therapy. In their study, it has been shown that 
patients with low MCs density had significantly better 
prognosis compared to those with high MCs density. In 
addition, Blatner et al[52] reported that in CRC, MCs con-
tribute to systemic regulatory T-cell dysfunction. MCs 
have an intricate interaction with T-regulatory cells that 
controls the functions of  both cell types in a reciprocal 
manner. MCs play also an important role in allograft ac-
ceptance, where they are required to sustain the periph-
eral tolerance mediated by T-regulatory cells. These latter 
can inhibit MCs differentiation and hinder degranulation 
by contact-dependent mechanisms and production of  
soluble factors, such as IL-10. Conversely, the activation 
and subsequent degranulation of  MCs breaks peripheral 
tolerance. MCs degranulation or direct cell contact and 
secretion of  IL-6 promote Th-17 conversion of  T-regu-
latory cells with loss of  both forkhead box P3 transcrip-
tion factor (Foxp3) expression and T-cell-suppressive 
properties.
Neutrophils may form up to 15% of  the inflamma-
tory infiltrate associated with CRCs and this proportion 
increases within areas of  tumor necrosis[28]. In patients 
with rectal cancer, high concentrations of  neutrophils 
have been shown as independent predictors of  improved 
prognosis especially when microscopic abscesses form[28]. 
However, an elevated neutrophil/lymphocyte ratio was, 
however, found by Halazun et al[53] led to a poorer sur-
vival time and higher rate of  recurrence in CRC patients 
undergoing surgery for liver metastasis. 
NK cells are granular lymphocytes that form part 
of  the innate cellular immune response[28]. In CRC, high 
numbers of  NK cells in the inflammatory infiltrate has 
been associated with better prognosis[28]. The number 
of  NK cells decreases with increasing cancer stage. Ad-
ditionally, it has been shown that the ratio of  NK cells in 
the peripheral blood is an important prognostic indicator 
in CRC patients and it is of  interest to note that 5-fluoro-
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balance between immune-surveillance (carried out by 
CD8+ and CD4+ T lymphocytes) and tumour-promoting 
inflammation (by various sub-types of  T lymphocytes) 
to change over time, and eventually dictating disease pro-
gression. It has been suggested that immune-surveillance 
might mediate the early recognition and elimination of  
transformed cells and aberrant crypt foci, keeping small 
tumours in a dormant state[62]. Immune-surveillance is 
retained important during the metastatic process, when 
small numbers or isolated tumoral cells travel and can 
be attacked by antitumor immune cells not inhibited by 
factors in the tumour microenvironment. Galon et al[18] 
suggested that once human CRC become clinically de-
tectable, the adaptive immune response plays a role in 
preventing tumour recurrence and metastasis. Independ-
ently, Chiba et al[63] and Banerjea et al[64] reported that 
intra-tumoral T cells modify the tumour stroma or CRC 
cells in a way that attenuate the metastatic potential.
Cytotoxic T lymphocytes (CD8+ T cells, or CTL) 
constitute one of  the leading effector of  antitumor 
immunity. In order for CD8+ T cells to recognize anti-
gens, these need to be exposed on the tumour cells in 
association with the human leukocyte antigen (HLA) 
class Ⅰ proteins[65]. Upon encounter of  a tumour cell 
antigen/HLA Ⅰ complex for which their T cell receptor 
(TCR) is specific, CD8+ T lymphocytes clonally expand 
and differentiate[65]. Once activated, cytotoxic T lym-
phocytes can mediate specific destruction of  tumour 
cells through the release of  lytic components via cell-cell 
interaction[65,66]. Perforin, a cytolytic protein found in the 
granules of  CD8 T-cells and NK cells, and enzymatic 
proteases, including granzyme B, are secreted determin-
ing cell death by disruption of  the cell membrane and 
activation of  the apoptotic pathway respectively. CD4+ 
T cells, which only respond to antigens presented by the 
HLA class Ⅱ proteins expressed by DCs, are important 
for antitumor immunity. On the peculiar cytokine profile 
induced, CD4+ T lymphocytes are mainly subdivided in 
Th1 or Th2 lymphocytes[67]. Th1 cells secrete cytokines 
such as interferon-gamma (IFN-γ) and TNF-α, and 
support cytotoxic T lymphocytes by producing IL-2, 
required for CD8+ T cells proliferation. Conversely, Th2 
cells principally secrete IL-10, IL-4, and IL-5, and limit 
cytotoxic T lymphocytes proliferation. 
Regulatory T cells (Treg cells) have been defined as 
a T-cell population that functionally suppresses an im-
mune response by influencing the activity of  another cell 
type[68]. Treg cells have been categorized into two main 
classes based on their ontogeny: naturally occurring Treg 
(nTreg), which develop in the thymus and are present in 
mice and healthy humans from an early postnatal period, 
and Treg which can arise in the periphery (or in vitro)[69]. 
nTreg are characterized by their high expression of  CD25 
(CD4+CD25+) and co-expression of  the FOXP3[69]. 
Needham et al[70] reported that depletion of  intra-tumoral 
Tregs enhances antitumor immunity and tumour rejec-
tion in mouse models. Clarke et al[71] have shown that 
depletion of  Tregs in the peripheral blood of  patients 
with CRC was recently shown to unmask CD4+ T-cell re-
sponses to tumour antigens. It is known that self-tumour 
antigens may also induce the preferential proliferation 
of  CD4+CD25+FOXP3+ Treg cells. Tregs function to 
maintain immune homeostasis and limit acute inflam-
mation. These cells interfere with T cell priming and can 
affect the antitumor function of  effector cells via secre-
tion of  TGF-β and IL-10. A number of  investigations 
suggest that Tregs infiltrating the tumour may adversely 
affect prognosis[72-75]. Increased levels of  Treg cells have 
been, however, associated with a favourable prognosis 
in CRC[76-79]. The mechanisms of  this dual effect, which 
seems dependent on the tissue type, are not well under-
stood, although it is hypothesized that Tregs might sup-
press inflammation induced by growth promoting innate 
immune system cells. 
Although the role of  B lymphocytes in cancer has 
been overshadowed by the interest in developing T-cell-
mediated cellular responses, it is now apparent that B 
lymphocytes can play a complementary role in the host 
response against tumour. B lymphocytes represent a cell 
population that express clonally diverse cell surface Ig 
receptors recognizing specific antigenic epitopes. In ad-
dition to the role of  B lymphocytes in antibody produc-
tion, these cells mediate/regulate several other functions 
fundamental for immune homeostasis. Of  significant im-
portance is the antigen-presenting role of  B lymphocytes 
in the initiation of  T-cell immune responses. Moreover, 
B lymphocytes can play a significant role in infection and 
autoimmunity as regulatory cells (indicated as Bregs) via 
the elaboration of  suppressive cytokines, such as IL-10, 
TGF-β, or IL-4. The role played by B cells in cancer 
immunology remains still complex and somewhat con-
troversial. Depending upon their state of  activation, B 
lymphocytes  have had divergent roles on T-cell differ-
entiation and effector function. Oversimplifying, resting 
B lymphocytes  have been reported to suppress T-cell-
mediated antitumor immunity, by acting on both CD4+ 
and CD8+ T lymphocytes. In contrast, a number of  
reports suggest the efficacy of  activated B lymphocytes 
in cellular immunotherapy of  malignancies. In particular, 
activated B lymphocytes  have been reported to enhance 
the ability to generate tumour-infiltrating lymphocytes in 
vitro involving anti-CD3 and IL-2.
The therapeutic targeting of  tumours or components 
of  the immune system with molecule-specific monoclo-
nal antibodies (mAb) is now considered a viable treat-
ment option for cancer patients. One of  the currently 
applied antibodies in clinics is represented by rituximab 
(Rituxan) that targets B cells for elimination by binding 
the B cell-associated marker CD20. Interestingly, it has 
been recently developed a C57BL/6 TRAIL-sensitive 
tumour model with the aim of  being able to use gene-
targeted mice to better evaluate the innate and adaptive 
immune cells contributing to the tumoricidal activity of  
the MD5-1 mAb in more clinically relevant established 
tumours. C57BL/6 gene-targeted or immune cell-deplet-
ed mice were used to examine the antitumor activity of  
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MD5-1 against the TRAIL-sensitive mouse MC38 colon 
adenocarcinoma. It has been shown that an intact B cell 
compartment is critical for the therapeutic activity of  
MD5-1 against established tumours. B cells were con-
firmed to trigger tumour cell apoptosis by FcR-mediated 
cross-linking of  the MD5-1 mAb in vitro and in vivo B 
lymphocytes were critical for directly triggering MD5-
1-mediated tumour cell apoptosis. 
Although the role of  B-cells in human CRCs is still 
not completely characterized, B-cell-deficient mice exhibit 
spontaneous regression of  MC38 colon carcinoma cells. 
Studies involving BCR transgenic mice indicated that 
B lymphocytes  might inhibit antitumor T lymphocytes 
responses by antigen-nonspecific mechanisms. Shah et al 
investigated the role of  B lymphocytes in tumour immu-
nity by studying immune responses of  mice genetically 
lacking B lymphocytes to primary tumours. They high-
light that although the effects of  B lymphocytes  on anti-
tumour response warrant further study, adoptive transfer 
of  CD40(-/-) B lymphocytes into B lymphocytes-defi-
cient mice resulted in restored growth of  MC38 colon 
carcinoma cells suggesting additional factors other than 
CD40 are involved in dampening anti-tumour responses. 
PROGNOSTIC INFORMATION OF 
IMMUNE CELL INFILTRATE 
In contrast to infiltration of  cells responsible for chronic 
inflammation, the presence of  high numbers of  T lym-
phocytes has been reported to be a positive prognostic 
factor in several cancers. The first reports on the benefi-
cial effect of  lymphocytic infiltration in CRC appeared 
already in the Eighties. They were later confirmed until 
recent most studies highlighting a prominent function 
for memory T lymphocytes and CD8+ T lymphocytes 
in predicting disease-free survival and overall survival. 
In general terms, it has been suggested that prognosis 
in patients with cancer is positively affected by (1) the 
presence of  a tumour gene signature consistent with a 
type Ⅰ adaptive immune response (i.e., increased antigen 
presentation, IFN-γ signalling, and TCR signalling); and 
(2) the presence of  T cells that penetrate through tumour 
stroma and deeply infiltrate the parenchyma to become 
intra-tumoral T cells[20]. Thus, besides a Th-1 response 
signature, the other key feature of  an effective immune 
response is the ability of  T cells to reach the site of  the 
tumour and to infiltrate it. Because T-cell infiltration is 
not spatially homogeneous in CRC, attention has been 
focused on the predictive values of  T lymphocytes lo-
cated in the center of  the tumor (CT), along the invasive 
margin (IM) and in lymphoid aggregate mainly detectable 
in proximity of  the tumor (these aggregates are called 
tertiary lymphoid structures)[80,81].
In a large series of  CRCs, Pagès et al[82] assessed the 
immune component of  the tumoral microenvironment 
by a combination of  high-throughput gene expression 
and immunophenotypic analyses, and evaluated its pos-
sible influence on tumour dissemination. They found 
an association between evidence of  an immune reaction 
within the tumour and the absence of  tumour local inva-
sion of  vascular, lymphatic, and neural structures (col-
lectively referred to as VELIPI). CRCs without VELIPI 
were associated with an enhanced immune cell infiltra-
tion and an increase of  mRNA expression of  adaptive 
Th1 effector T-cell markers [CD8, T-box transcrip-
tion factor 21 (T-bet), IFN regulatory factor-1 (IRF-1), 
IFN-γ, granulysin, and granzyme B]. The immunohisto-
chemical analysis of  adaptive immune markers i.e., CD3, 
CD8, granzyme B, and CD45RO, by tissue microarrays 
prepared from the CT and from its IM revealed a sta-
tistically significant correlation between the density of  
these immune cells and outcome for all patients but 
those with metastatic disease at diagnosis. Further, the 
combined analysis of  both tumour regions improved the 
accuracy of  survival prediction compared with single-
region analysis[18].
Independently, Deschoolmeester et al[83] showed that 
the presence of  a pronounced lymphocytic infiltration 
within the tumour is associated with improved survival. 
They found that CD3+ and CD8+ T lymphocytes within 
tumour nests and of  CD3+ in the stroma had a major 
impact on the patients’ overall survival. The improved 
survival associated with infiltration of  T lymphocytes has 
been suggested to result from the effective suppression 
of  micrometastases. Therefore, the densities of  CD8+ 
T cells within the primary tumour might be a potential 
marker of  the presence of  a systemic immunosurveil-
lance mechanism. In addition, tumour cells secrete sub-
stances in the stromal compartment, which might be rec-
ognized by the immune system that subsequently attack 
the tumour. A weak adaptive immune reaction correlated 
with a very poor prognosis even in patients with early tu-
mour invasion. Conversely, a high density of  adaptive im-
mune cells correlated with a highly favourable prognosis 
whatever the local extent of  the tumour and the regional 
lymph node invasion. 
In mice, targeted disruptions of  genes that encode 
critical components of  the immune system (i.e., mice 
lacking: IFN-γ or its receptor, signal transducer and acti-
vator of  transcription-1 mediating IFN-γ receptor signal-
ling, perforin, recombination activating gene-2, or IL-12) 
induce an increased susceptibility of  the host to tu-
mours[84]. These findings make it possible to hypothesize 
an immune-mediated control of  tumour development by 
the adaptive compartment. 
A number of  studies have reported that MSI, CIMP, 
BRAF mutation, PIK3CA mutation, and tumour LINE-1 
hypomethylation are associated with CRC prognosis and 
that lymphocytic infiltration is associated with many of  
these molecular variables. The associations of  a prog-
nostic biomarker with a given disease, strongly suggests 
its stage-dependency as outcome predictor. This is best 
exemplified by MSI CRC, whose overall prognostic ad-
vantage is associated with a low frequency of  stage Ⅲ 
and Ⅳ cases at diagnosis as compared to microsatellite 
stable counterpart. Most MSI CRCs show a pronounced 
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intra-tumoral inflammatory reaction (in fact a criterion 
for MSI testing), the mechanistic explanation of  which, 
however, is still incompletely understood. Within these 
tumours, infiltrating lymphocytes have been identified 
as predominantly activated CD8+ T cells. The presence 
of  these cytotoxic T lymphocytes has been attributed to 
the inherently greater production of  abnormal peptides 
as a result of  unreliable DNA repair in MSI-positive tu-
mours. It is known that truncated peptides produced by 
frameshift mutations due to MSI may be immunogenic 
and contribute to the host immune response. However, 
little is still known about the interrelationship between 
tumour-infiltrating T lymphocytes, MSI status, and other 
tumour molecular features. It is indubitable that to define 
the prognostic effect of  tumour-infiltrating T-cells inde-
pendently of  those potential confounders, large studies 
of  CRC with extensive molecular characterization are 
needed. Additionally, caution is needed before incorpo-
rating tumour-infiltrating T cells into tumour staging. To 
minimise the risk of  inappropriate tumour down-staging 
at diagnosis, survival data need to be confirmed in in-
dependent series of  patients studied in the past decade. 
Moreover, the association has to be conclusively proven 
between low densities of  tumour-infiltrating T cells 
and the clinical detection of  metachronous metastases, 
which remains the most appropriate outcome measure 
for recognising a role of  the local immune response in 
micrometastasis suppression. Recently, Laghi et al[85] in-
vestigated the relationship between the density of  CD3+ 
T infiltrating lymphocytes along the tumour invasive mar-
gin, and the occurrence of  metachronous distant-organ 
metastases after potentially curative resection, in a large, 
consecutive series of  patients with deeply invading (pT3 
or pT4) MSI-typed CRC, and no evidence of  distant or-
gan metastasis at diagnosis. They found that large areas 
of  CD3+ cells at the invasive front of  pT3 or pT4 CRCs 
are associated with a low risk of  metachronous metasta-
sis and consequently a survival advantage, only in patients 
with node-negative cancers, but not in patients whose 
cancers involved lymphnodes. Of  interest, the prognostic 
advantage conferred by a high density of  CD3+ cells was 
independent of  tumour microsatellite status in patients 
with stage Ⅱ CRC. CD3-immunostaining of  CRC tissue 
might therefore be useful for selecting stage Ⅱ patients 
who, because they are at very low risk for cancer progres-
sion, could be spared adjuvant treatments.
Nosho et al [86] examined the prognostic role of  
tumour-infiltrating T-cell subsets in a database of  768 
CRCs from two prospective cohort studies. They concur-
rently assessed the densities of  CD3+, CD8+, CD45RO+, 
and FOXP3+ lymphocytes as well as other relevant mo-
lecular and pathological features, therefore making pos-
sible to evaluate the independent effect of  each T-cell 
subset density on patient survival. They found that the 
density of  CD45RO+ cells, but not that of  CD3+, CD8+, 
or FOXP3+ cells, was an independent prognostic bi-
omarker of  longer survival in CRC patients. In contrast, 
Salama et al[76] by analysing T-cell infiltrates in 967 CRCs 
including 593 stage Ⅱ and 374 stage Ⅲ cases, reported 
that FOXP3+ lymphocytes density had stronger prog-
nostic significance than CD8+ and CD45RO+ cells, and 
predicted a better outcome. FOXP3+ lymphocytes were 
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Figure 2  Anti- and pro-tumor immune response involves the interaction of several cell types of the adaptive as well as of the innate immune system, and 
an intricate network of products (i.e., cytokines and chemokines). IL: Interleukin; INF-γ: Intracellular interferon-γ; EGF: Epidermal-growth factor; NK cells: Natural 
killer cells. 
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found not associated with any histopathologic features. 
At multivariate analysis, stage, vascular invasion, and 
FOXP3+ cell density in tumoral tissue were independent 
prognostic indicators. These results led Salama et al[76] to 
conclude that the inclusion of  FOXP3+ cell density may 
help to improve the prognostication of  early-stage CRC, 
although these authors do not explored this parameter 
with tumor stage. 
CONCLUSION
It is accepted that human cancer is a complex dynamical 
disease[87,88]. It is also now well recognized that cancers 
are not just composed of  malignant cells, but that they 
are microenvironment consisting of  many cell types, in-
cluding a range of  immune cells. It is indubitable that the 
antitumor immune response involves the interaction of  
several cell types and products (Figure 2), of  the adaptive 
as well as of  the innate immune system. It is also clear 
that CRC can escape immune surveillance using several 
strategies. The molecular profiles of  the function and 
interaction of  innate and adaptive immune cells, and the 
definition of  tumor antigens have all led to build the ba-
sis of  the knowledge of  how the immune system modu-
lates tumor growth and inhibition. The challenge remains 
to determine not only how the “rejection” pathway initi-
ates in human malignancy, but also how that rejection is 
maintained. It is indubitable that the analysis of  the type, 
quantity, location and the functions of  the immune infil-
trate becomes a primary step in understanding CRC natu-
ral history, and, in a clinical perspective, its prognostic de-
terminants. A comprehensive analysis of  all components 
of  the lymphocytic infiltrates in the context of  their 
localization, organization and impact at various steps of  
tumor progression remains largely, if  not entirely, to be 
reported to prospective studies. In parallel, understanding 
the mechanisms of  efficient immune reactions, the place 
where they are initiated, the cells and key cytokines and 
chemokines involved (Figure 2), and their impact at dif-
ferent stages of  the disease should provide new tools and 
goals for more effective and less toxic targeted therapies.
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